

Emtricitabine/tenofovir disoproxil fumarate  
200 mg/300 mg tablets  
(Hetero Labs Limited), HA498

WHOPAR part 5

April 2020

## **LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING**

**Carton and bottle label (HDPE bottle)**

**1. NAME OF THE MEDICINAL PRODUCT**

[HA498 trade name]<sup>1</sup>

**2. STATEMENT OF ACTIVE SUBSTANCE**

Each film-coated tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil or 136 mg of tenofovir).

**3. LIST OF EXCIPIENTS**

Contains lactose.  
See the patient information leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

28 Tablets  
30 Tablets  
56 Tablets  
60 Tablets

**5. METHOD AND ROUTE OF ADMINISTRATION**

Oral use.  
Read the patient information leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP {MM/YYYY}

<sup>1</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

**9. SPECIAL STORAGE CONDITIONS**

Store below 30°C, protect from light and keep in tightly closed containers.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE SUPPLIER**

Hetero Labs Limited  
7-2-A2, Hetero Corporate,  
Industrial Estates, Sanath Nagar,  
Hyderabad – 500 018, Telangana, INDIA  
Tel: 0091-40-23704923/24/25

**12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)**

HA498

**13. MANUFACTURER'S BATCH NUMBER**

<Batch> {number}

**14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**